Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.56, $0.02 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $404.2 million versus the consensus estimate of $394.62 million.

GUIDANCE:

Amedisys sees FY2018 EPS of $2.97-$3.08, may not compare to the consensus of $2.66. Amedisys sees FY2018 revenue of $1.6-1.64 billion, versus the consensus of $1.63 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.